Stock Research for XXII

XXII

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

XXII Stock Chart & Research Data

The XXII chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the XXII chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


XXII Due diligence Resources & Stock Charts

The XXII stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View XXII Detailed Price Forecast - CNN Money CNN View XXII Detailed Summary - Google Finance
Yahoo View XXII Detailed Summary - Yahoo! Finance Zacks View XXII Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View XXII Trends & Analysis - Trade-Ideas Barrons View XXII Major Holders - Barrons
NASDAQ View XXII Call Transcripts - NASDAQ Seeking View XXII Breaking News & Analysis - Seeking Alpha
Spotlight View XXII Annual Report - CompanySpotlight.com OTC Report View XXII OTC Short Report - OTCShortReport.com
TradeKing View XXII Fundamentals - TradeKing Charts View XXII SEC Filings - Bar Chart
WSJ View Historical Prices for XXII - The WSJ Morningstar View Performance/Total Return for XXII - Morningstar
MarketWatch View the Analyst Estimates for XXII - MarketWatch CNBC View the Earnings History for XXII - CNBC
StockMarketWatch View the XXII Earnings - StockMarketWatch MacroAxis View XXII Buy or Sell Recommendations - MacroAxis
Bullish View the XXII Bullish Patterns - American Bulls Short Pains View XXII Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View XXII Stock Mentions - StockTwits PennyStocks View XXII Stock Mentions - PennyStockTweets
Twitter View XXII Stock Mentions - Twitter Invest Hub View XXII Investment Forum News - Investor Hub
Yahoo View XXII Stock Mentions - Yahoo! Message Board Seeking Alpha View XXII Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for XXII - SECform4.com Insider Cow View Insider Transactions for XXII - Insider Cow
CNBC View XXII Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for XXII - OTC Markets
Yahoo View Insider Transactions for XXII - Yahoo! Finance NASDAQ View Institutional Holdings for XXII - NASDAQ


Stock Charts

FinViz View XXII Stock Insight & Charts - FinViz.com StockCharts View XXII Investment Charts - StockCharts.com
BarChart View XXII Stock Overview & Charts - BarChart Trading View View XXII User Generated Charts - Trading View




Latest Financial News for XXII


22nd Century Group to Participate in Investor Conferences in March 2021
Posted on Friday March 05, 2021

WILLIAMSVILLE, N.Y., March 05, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, today announced that members of its management team will participate in three investor conferences during March 2021. Institutional investors and those invited to attend these virtual conference events may request one-on-one meetings with representatives of the Company through the respective conference hosts or by contacting 22nd Century Group’s investor relations via mkuo@xxiicentury.com. Events 22nd Century Group will participate in include: The DA Davidson 4th Annual Consumer Growth Conference, March 11, 2021One-on-one meetings will be available on the afternoon of Thursday, March 11. To request a meeting, please contact your DA Davidson sales representative. The 33rd Annual Roth Conference, March 15-17, 2021One-on-one and small group meetings will be available on Tuesday, March 16. Additional times may be available to accommodate meeting requests as needed. To request a meeting, please contact your Roth sales representative. The Investor Summit Virtual Conference, March 23-25, 2021James A. Mish, chief executive officer of 22nd Century, will provide an overview presentation of the Company. An audio webcast of the presentation will be available through 22nd Century’s Events web page in the Company's Investor Relations section of the website, at www.xxiicentury.com/investors/events. One-on-one meetings will be available on Tuesday, March 23. To request a meeting, please contact your Investor Summit Group representative. About 22nd Century Group, Inc.22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding. 22nd Century’s primary mission in tobacco is to reduce the harm caused by smoking through the Company’s proprietary reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes. The Company’s primary mission in hemp/cannabis is to develop and commercialize proprietary hemp/cannabis plants with valuable cannabinoid profiles and desirable agronomic traits. Learn more at xxiicentury.com, on Twitter @_xxiicentury, and on LinkedIn. Cautionary Note Regarding Forward-Looking StatementsExcept for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 11, 2020, and in its subsequently filed Quarterly Report on Form 10-Q. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law. Investor Relations & Media Contact:Mei KuoDirector, Communications & Investor Relations22nd Century Group, Inc.(716) 300-1221mkuo@xxiicentury.com


Will 22nd Century Group (XXII) Report Negative Earnings Next Week? What You Should Know
Posted on Thursday March 04, 2021

22nd Century (XXII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.


22nd Century Group Receives $8.1 Million from Cash Exercise of Outstanding Warrants
Posted on Thursday March 04, 2021

WILLIAMSVILLE, N.Y., March 04, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, today announced that it has received net proceeds of $8.1 million from the cash exercise of outstanding warrants during February and March of 2021. The remaining warrants, if exercised for cash, will bring additional net proceeds of $3.7 million in cash to the Company. Following the above transaction, the Company will no longer have any outstanding warrants. “We are pleased to further strengthen our balance sheet with $8.1 million from the exercise of these existing warrants that were already a consideration in our fully diluted capital structure,” said James A. Mish, chief executive officer of 22nd Century Group. “The capital will provide us with additional runway to further fuel our current operations, strategy, and growth initiatives including near-term opportunities in both our tobacco and hemp/cannabis franchises. We look forward to securing Modified Risk Tobacco Products (MRTP) authorization, launching VLN®, and building the VLN® brand. The additional cash will also support our hemp/cannabis R&D initiatives and the development of our third franchise in 2021.” About 22nd Century Group, Inc.22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding. 22nd Century’s primary mission in tobacco is to reduce the harm caused by smoking through the Company’s proprietary reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes. The Company’s primary mission in hemp/cannabis is to develop and commercialize proprietary hemp/cannabis plants with valuable cannabinoid profiles and desirable agronomic traits. Learn more at xxiicentury.com, on Twitter @_xxiicentury, and on LinkedIn. Cautionary Note Regarding Forward-Looking StatementsExcept for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 11, 2020, and in its subsequently filed Quarterly Report on Form 10-Q. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law. Investor Relations & Media Contact:Mei KuoDirector, Communications & Investor Relations22nd Century Group, Inc.(716) 300-1221mkuo@xxiicentury.com


22nd Century Group Secures Exclusive Agreement with CannaMetrix to Accelerate Commercialization of New, Disruptive Hemp/Cannabis Plant Lines and Intellectual Property
Posted on Wednesday March 03, 2021

High-throughput technology will dramatically advance and reduce timeframe for bringing valuable, commercial hemp/cannabis plant lines and intellectual property to market in two yearsWILLIAMSVILLE, N.Y., March 03, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it has secured an exclusive agreement with CannaMetrix, LLC for the use of their proprietary, human cell-based testing CannaMetrix EC50Array™ technology that will enable 22nd Century to accelerate the commercialization of new, disruptive hemp/cannabis plant lines and intellectual property. Since reporting third quarter earnings, 22nd Century has refocused its hemp/cannabis strategy to target the upstream segments of the cannabinoid value chain. In particular, the Company seeks to accelerate the delivery of valuable, commercial-scale plant lines and intellectual property for the life science, consumer product, and pharmaceutical end-use markets. With the addition of CannaMetrix, 22nd Century has now secured four out of the five key partnerships needed to maximize each component in the upstream segment of the cannabinoid value chain: plant profiling (CannaMetrix), plant biotechnology (KeyGene), plant cultivation (Panacea-Needle Rock Farm), and ingredient extraction/purification (Panacea). The Company is also in final discussions with top-tier, plant breeders that will be announced soon. “22nd Century is extremely excited to add CannaMetrix into our secured network of value chain partners to increase the speed at which we develop and offer disruptive plant lines and intellectual property for the hemp/cannabis industry. For example, a plant line that would typically take ten years or longer to develop can now be achieved in two years,” said James A. Mish, chief executive officer of 22nd Century Group. “As we monetize our current IP portfolio starting in 2021, our upstream hemp/cannabis partnerships will enable us to rapidly offer additional disruptive, commercially valuable plant lines at large scale and increased, stable yields to very attractive hemp/cannabis end-use markets. We are excited and absolutely confident in the future innovation and value creation that will stem from these coordinated strategic partnerships.” “We are thrilled to collaborate with 22nd Century Group,” stated Harold Smith, Ph.D. founder, and chief executive officer of CannaMetrix. “They are the ideal partner, bringing decades-long experience in plant biotechnology with unmatched ability in developing valuable, commercial plant lines. We believe that through this exclusive partnership the development of new hemp/cannabis lines for large-scale cultivation and production will advance at a rapid pace and transform the hemp/cannabis industry.” CannaMetrix’s proprietary CannaMetrix EC50Array™ technology serves as a high-throughput roadmap for developing new hemp/cannabis plant lines with tailor-made cannabinoid and terpenoid profiles for use in the life science, consumer product, and pharmaceutical markets. The human cell-based assay has the ability to measure and validate the potency and efficacy of cannabinoids and/or terpenoids through defined biomarkers and receptor activity, and can rapidly identify optimum plant profiles by measuring the potency and effect on the human cell system. About CannaMetrix, LLC.Founded in 2016, CannaMetrix, LLC is a leader in gene and cell engineering. Their method development has focused on rapid, human cell-based testing with their proprietary CannaMetrix EC50Array™ technology. This technology measures, validates, and quantifies the potency and efficacy of cannabinoids and terpenoids derived from plants or synthetic products in living human cells. CannaMetrix addresses an unmet need in the industry with their rapid test of cannabis product potency based on actual biological responses to products that currently can only be inferred from chemical composition analyses of plant materials. Characterizing products by their chemical content and ability to evoke defined biological effects will be crucial to the development of differentiated products for the consumer end-market. The EC50Array™ technology will help accelerate development and calibrate cannabis lines for specific applications. About 22nd Century Group, Inc.22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding. 22nd Century’s primary mission in tobacco is to reduce the harm caused by smoking through the Company’s proprietary reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes. The Company’s primary mission in hemp/cannabis is to develop and commercialize proprietary hemp/cannabis plants with valuable cannabinoid profiles and desirable agronomic traits. Learn more at xxiicentury.com, on Twitter @_xxiicentury, and on LinkedIn. Cautionary Note Regarding Forward-Looking StatementsExcept for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 11, 2020, and in its subsequently filed Quarterly Report on Form 10-Q. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law. Investor Relations & Media Contact:Mei KuoDirector, Communications & Investor Relations22nd Century Group, Inc.(716) 300-1221mkuo@xxiicentury.com


Stock Market & Investing Books

Enter a stock symbol to view the stock details.